Neal Koller

Company: Alphyn Biologics

Job title: Chief Executive Officer

Seminars:

Market Leading Results from Phase 2 Clinical Trial: Multi-Target Therapeutics in Atopic Dermatitis and Epidermolysis Bullosa 12:00 pm

Discover the innovative multi-target therapeutics with market-leading results in Atopic Dermatitis and Epidermolysis Bullosa Uncover the robust clinical evidence supporting multiple mechanisms of action, including anti-inflammatory, anti-itch, and antibacterial properties Dive into the comprehensive safety profile of AB101-a, a game-changer for Atopic DermatitisRead more

day: Day Two Translational Track AM